DNA Damage

Items 101-150 of 3581

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. 5-Fluorouridine is a metabolite of 5-fluorouracil with anticancer activity.
  2. Topoisomerase inhibitor

    Amonafide is a DNA intercalator and topoisomerase II inhibitor for the treatment of neoplastic diseases, one of Antitumor agent.

  3. HDAC3 inhibitor

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM, exhibits > 200-fold selectivity over other HDAC.
  4. Topoisomerase IV inhibitor

    Ciprofloxacin Hydrochloride is a broad-spectrum antimicrobial carboxyfluoroquinoline, interfering with the bacterial DNA gyrase, inhibiting the DNA synthesis, and preventing bacterial cell growth.
  5. PARP1 inhibitor

    AG14361 is a potent PARP inhibitor, enhanced TMZ cytotoxicity in MMR(mismatch repair)-proficient / deficient cells.
  6. Topoisomerase inhibitor

    Idarubicin is an anthracycline antibiotic that is an anti-leukemia agent with higher DNA binding capacity and greater cytotoxicity than daunorubicin.
  7. PI3K inhibitor

    Wortmannin is a potent, selective, cell-permeable and irreversible inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase) (IC50 = 2 - 4 nM) which also potently inhibits polo-like kinase 1 (PLK1) (IC50 = 5.8 nM).

  8. PARP inhibitor

    PJ 34 hydrochloride is a potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC50 = 20 nM).
  9. Hoechst 33258 trihydrochloride is a cell dye for DNA quantitation.
  10. Protein Synthesis Inhibitor

    Cycloheximide (also known as actidione) is used as an selective antibiotic. It inhibits the protein synthesis (DNA-dependent RNA) of saprobic fungi eukaryotes. by binding with the 80S ribosome, while inactive against dermatophytes and systemic fungi.
  11. DNA topoisomerase II inhibitor

    Beta-Lapachone is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase.
  12. DNA/RNA Synthesis inhibitor

    Clofarabine is a second generation purine nucleoside analog with antineoplastic activity
  13. Topoisomerase inhibitor

    Epirubicin is a cell-permeable antitumor antibiotic. A stereoisomer of Doxorubicin that exhibits reduced cardiotoxicity. Epirubicin?€?s antitumor actions are mediated by targeting and inhibiting Topo II (topoisomerase II).
  14. Selective SIRT2 inhibitor

    SirReal2 is a potent and selective Sirt2 inhibitor with IC50 of 140 nM.
  15. DNA/RNA Synthesis inhibitor

    Oxaliplatin is a platinum-based antineoplastic agent that is used in cancer chemotherapy. In vivo studies showed that Oxaliplatin has anti-tumor activity against colon carcinoma through its (non-targeted) cytotoxic effects.
  16. ATM inhibitor

    AZD0156 is a potent and selective inhibitors of ATM kinase, with potential chemo-/radio-sensitizing and antineoplastic activities.
  17. DNA synthesis inhibitor

    Gemcitabine (LY 188011) is a DNA synthesis inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.
  18. ATM/ATR inhibitor

    VE-821 is a potent and selective inhibitor of protein kinase ATR.
  19. HDAC inhibitor

    TMP 269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
  20. HDAC inhibitor

    AR-42 is a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.
  21. DNA/RNA Synthesis inhibitor

    Raltitrexed (Tomudex) is an inhibitor of thymidylate synthase and also is one of the strongest antimetabolites in use.
  22. PARP inhibitor

    Olaparib (AZD2281) is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
  23. DDX3 inhibitor

    RK-33 is a potent and selective DDX3 inhibitor. RK-33 binds to DDX3 and abrogates its activity.
  24. NKP-1339 (IT-139) is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer with limited side effects.
  25. eIF4E-eIF4G interaction inhibitor

    4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM.
  26. HCV NS5B polymerase inhibitor

    VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
  27. SIRT1/SIRT2 inhibitor

    Cambinol is a SIRT1 and SIRT2 inhibitor with IC50 values of 56 and 59 μM, respectively.
  28. PARP Inhibitor

    AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
  29. Apaziquone is an indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities.
  30. HDAC6 inhibitor

    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5?nM.
  31. HDAC1/HDAC2 inhibitor

    BRD-6929 (Cpd-60) is a brain-penetrant, selective inhibitor of HDAC1 and HDAC2 (IC50=?1 and 8 nM), extracted from patent US2018360927.
  32. IRE1α RNase kinase inhibitor

    KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC50 of 0.6 ?M. KIRA6 can trigger an apoptotic response.
  33. SIRT1 inhibitor

    Inauhzin is a potent SIRT inhibitor, which effectively reactivates p53 by inhibiting SIRT1 activity, promotes p53-dependent apoptosis of human cancer cells without causing apparently genotoxic stress.
  34. Topoisomerase I inhibitor

    9-Aminocamptothecin is a topoisomerase I inhibitor with potent anticancer activity.
  35. HDAC inhibitor

    Resminostat, also known as RAS2410, is a potent inhibitor of histone deacetylase (HDAC) classes I and II. It binds to and inhibits HDACs leading to an accumulation of highly acetylated histones.
  36. topoisomerase II inhibitor

    Ametantrone (AM) is a synthetic 9,10-anthracenedione bearing two (hydroxyethylamino)ethylamino residues at positions 1 and 4 along with other anthraquinones and anthracyclines.
  37. HDAC4 inhibitor

    Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.
  38. Fosteabine is an oral and prodrug analogue of cytarabine which is resistant to deoxycytidine deaminase.
  39. Topoisomerase II inhibitor

    Amrubicin is a synthetic anthracycline antibiotic. It inhibits DNA topoisomerase II. Antineoplastic.
  40. DHFR inhibitor

    Pemetrexed is a novel antifolate with multiple targets
  41. Palifosfamide is a synthetic mustard compound with potential antineoplastic activity.
  42. HDAC inhibitor

    Scriptaid is an HDAC inhibitor (histone deacetylase).
  43. HDAC inhibitor

    Apicidin is a a potent histone deacetylases (HDAC) inhibitor with potential anticancer activity.
  44. PARP2 inhibitor

    UPF 1069 is a selective poly(ADP-ribose) polymerase (PARP) 2 inhibitor (IC50 values are 0.3 and 8.0 μM for PARP-2 and PARP-1 respectively).
  45. topoisomerase I inhibitor

    Gimatecan is an orally bioavailable, semi-synthetic lipophilic analogue of camptothecin, a quinoline alkaloid extracted from the Asian tree Camptotheca acuminate, with potential antineoplastic and antiangiogenic activities.
  46. natural cyclic oligopeptide antibiotic

    Antibiotic that inhibits bacterial protein synthesis. Inhibits mRNA-tRNA translocation by GTPase elongation factor G (EF-G), EF-TU(GTP)-catalyzed aa-tRNA delivery and the activity of initiation factor 2 (IF-2). Antitumor agent; induces cell cycle arrest and apoptosis in breast cancer cells via downregulation of FOXM1 expression.
  47. SIRT2 inhibitor

    AK-7 is a cell- and brain-permeable inhibitor of SIRT2 (IC50 = 15.5 μM).
  48. HDAC6 inhibitor

    BRD9757 is a highly potent and selective HDAC6 inhibitor with an IC50 of 30 nM toward HDAC6.
  49. eIF4A3 inhibitor

    eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC50=0.26 μM; Kd=0.043 μM).
  50. HQL-79 is a selective inhibitor of hematopoietic prostaglandin D (PGD) synthase, that structurally is a synthetic tetrazole compound originally prepared as a possible antihistamine.

Items 101-150 of 3581

Page
per page
Set Descending Direction